Literature DB >> 22188158

Considerations in the development of an in vitro dissolution condition for lacidipine tablets: in vivo pharmacokinetic evaluation.

Mingyu Sun1, Jin Sun, Shuangfeng He, Yongjun Wang, Yinghua Sun, Xiaohong Liu, Zhonggui He.   

Abstract

In this study, a new discriminative dissolution condition for lacidipine tablets was developed by the established in vitro-in vivo relationship. Series of dissolution media of phosphate buffer solution (PBS) covering the pH range of 1-7.2 and pH 6.8 PBS containing different concentrations of sodium dodecyl sulfate (SDS), were prepared and used to investigate the dissolution behavior of lacidipine tablets. There was an obvious difference in the dissolution profiles of the both brands in pH 6.8 PBS medium containing 0.1% SDS. The pharmacokinetic study of the two lacidipine tablets was carried out in the healthy beagle dogs at a single dose of 4 mg. Statistical comparison of the AUC(₀₋₂₄), C(max), and T(max) showed a significant difference in the two brand tablets, coinciding with the dissolution performance with pH 6.8 PBS containing 0.1% SDS. The superiority of the proposed system, pH 6.8 PBS containing 0.1% SDS, could serve as a dissolution medium for lacidipine tablets, and more important it could discriminate the in vivo pharmacokinetic behavior for different brands of products. In summary, in vivo pharmacokinetic evaluation is essential to develop an appropriate in vitro dissolution condition for oral solid dosage forms of poorly soluble drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22188158     DOI: 10.3109/03639045.2011.641561

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  1 in total

1.  In vitro/vivo assessment of praziquantel nanocrystals: Formulation, characterization, and pharmacokinetics in beagle dogs.

Authors:  Ruyi Yang; Tao Zhang; Jiang Yu; Yan Liu; Yingli Wang; Zhonggui He
Journal:  Asian J Pharm Sci       Date:  2018-08-17       Impact factor: 6.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.